REGINfo: VIFOR PHARMA - Pharmacie - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
- Remgro
- RICHEMONT
- RMB Holdings
- Sanlam
- Sasol
- Shoprite
- Standard Bank Group
- Tiger Brands
- Vodacom Group
- WOOLWORTHS
> TA 25
Israel - TA 25
- AVNER OIL
- AZRIELI GROUP
- BEZEQ
- DELEK DRILLIN
- DISCOUNT
- ELBIT SYSTEMS
- FIBI BANK
- GAZIT GLOBE
- ICL
- IFF
- ISRAEL CORP
- KENON
- LEUMI
- MIGDAL INSURANCE
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- OSEM
- PAZ OIL
- PERRIGO
- POALIM
- STRAUSS GROUP
- TEVA

Europe

COMPANY SEARCH RESULT

$VIFOR PHARMA: Click to view the issuer\'s details$

Last update : 21/08/2018 >View issuer details

2019.05.21 | 05:00 | Permanent Information Releases / General Company News

puce First patient treated in DIAMOND study to evaluate if Veltassa® (patiromer) improves outcomes by enabling long-term use of essential RAASi therapy - HTML (w)

2019.05.10 | 19:30 | Permanent Information Releases / General Company News

puce Vifor Pharma’s Phase-II AMBER Study Meets Primary Endpoint - HTML (w)

2019.05.08 | 15:48 | Annual General Meeting / AGM

puce 91st Vifor Pharma Group Annual Shareholder Meeting - HTML (w)

2019.05.08 | 15:48 | Annual General Meeting / AGM

puce 91e Assemblée Générale du Groupe Vifor Pharma - HTML (w)

2019.04.09 | 05:00 | Permanent Information Releases / General Company News

puce Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement - HTML (w)

2019.03.14 | 06:00 | Permanent Information Releases / Sales and Revenues

puce LE GROUPE VIFOR PHARMA PUBLIE DE SOLIDES RÉSULTATS 2018 SUPÉRIEURS AUX PRÉVISIONS - HTML (w)

2019.03.14 | 06:00 | Permanent Information Releases / Sales and Revenues

puce Vifor Pharma Group Reports Strong 2018 Results, Exceeding Raised Guidance - HTML (w)

2019.03.07 | Periodic information / Annual Financial Report

puce VIFOR PHARMA : ANNUAL REPORT 2018 - PDF (13Mb)

2019.01.24 | 06:00 | Permanent Information Releases / General Company News

puce ChemoCentryx Announces Withdrawal of Phase II-Based Conditional Marketing Authorisation (CMA) Application for ANCA-Associated Vasculitis in Europe, Phase III Advocate Trial Data Release Planned for Q4 2019 - HTML (w)

2019.01.22 | 06:00 | Permanent Information Releases / General Company News

puce Updated Analysis of Pivotal Study Reveals: Proactive, High Dosage of Venofer® Significantly Reduces Risk of Death or Major Cardiovascular Events in Haemodialysis Patients - HTML (w)

2019.01.07 | 06:00 | Permanent Information Releases / General Company News

puce Vifor Pharma receives positive phase-I trial results for oral ferroportin inhibitor - HTML (w)

2019.01.07 | 06:00 | Permanent Information Releases / General Company News

puce Vifor Pharma obtient des résultats d’essai de phase I positifs pour l’inhibiteur de la ferroportine administré par voie orale - HTML (w)

2018.12.12 | 06:00 | Permanent Information Releases / Appointments

puce Patrick Treanor appointed President of Relypsa and member of the Executive Committee of Vifor Pharma Group - HTML (w)

2018.11.26 | 06:00 | Permanent Information Releases / General Company News

puce 2018 Iron Deficiency Day: A Call to Develop a Better Understanding of Iron Deficiency - HTML (w)

2018.08.08 | Periodic information / Half-Year Financial Report

puce VIFOR PHARMA : HALF-YEAR REPORT 2018 - PDF (746Kb)

Pages : 1 - 2 / Doc nb : 16